Fang Min, Tao Yifeng, Liu Zhimin, Huang Hao, Lao Min, Huang Lingsha, Zhu Bo
Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Biomed Res Int. 2017;2017:8047183. doi: 10.1155/2017/8047183. Epub 2017 Mar 16.
The prognostic value of reduced NM23 expression for gastric cancer (GC) patients is still contradictory. Thus, we conducted a meta-analysis to quantitatively evaluate the association of NM23 expression with GC risk and clinical features by analyzing 27 publications. The result of our meta-analysis indicated that NM23 expression is markedly reduced in gastric cancer tissues (OR = 3.15; 95% CI = 1.97-5.03; < 0.001). Furthermore, NM23 expression was negatively correlated with N stage, TNM stage, and histological grade. However, NM23 expression was not correlated with T stage, lymphatic invasion, vascular invasion, and 5-year overall survival rate. In conclusion, reduced NM23 expression correlated with gastric cancer risk, but its association with GC clinical features remains inconclusive. Therefore, large-scale and well-designed studies, which use uniform antibody and criterion of NM23 positive expression, are required to further validate the role of the NM23 in predicting GC progression.
NM23表达降低对胃癌（GC）患者的预后价值仍存在矛盾。因此，我们进行了一项荟萃分析，通过分析27篇文献来定量评估NM23表达与GC风险及临床特征之间的关联。我们的荟萃分析结果表明，胃癌组织中NM23表达明显降低（OR = 3.15；95%CI = 1.97 - 5.03；< 0.001）。此外，NM23表达与N分期、TNM分期及组织学分级呈负相关。然而，NM23表达与T分期、淋巴浸润、血管浸润及5年总生存率无关。总之，NM23表达降低与胃癌风险相关，但其与GC临床特征的关联仍无定论。因此，需要大规模且设计良好的研究，使用统一的抗体和NM23阳性表达标准，以进一步验证NM23在预测GC进展中的作用。
